PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
Abstract: we have performed the first-ever comparative pharmacoeconomic analysis in a Russian context of bendamustine in the first line of therapy of a multiple myeloma for for patients more senior 65 years old with clinical manifestations of a polineuropathy, which autological transplantation of st...
Saved in:
Main Authors: | A. S. Kolbin (Author), I. A. Vilum (Author), Yu. E. Balykina (Author), M. A. Proskurin (Author) |
---|---|
Format: | Book |
Published: |
IRBIS LLC,
2015-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD
by: A. S. Kolbin, et al.
Published: (2015) -
Pharmacoeconomic analysis of the use of ibrutinib in therapy of the first line of a chronic lymphocytic leukaemia for patients with 17p deletion
by: A. S. Kolbin, et al.
Published: (2018) -
Pharmacoeconomic analysis of botulinum toxin in complex therapy for cerebral palsy
by: A. S. Kolbin, et al.
Published: (2018) -
Pharmacoeconomic analysis of the use of botulinum toxin in the treatment of poststroke spasticity
by: A. S. Kolbin, et al.
Published: (2018) -
Pharmacoeconomic analysis of Flemoclav Solutab® use in adult patients with acute sinusitis in routine outpatient clinical practice in Russia
by: A. S. Kolbin, et al.
Published: (2018)